Read by QxMD icon Read

Brain tumor recurrence

Mary Lou Affronti, Jennifer Gamboa Jackman, Frances McSherry, James E Herndon, Elwood C Massey, Eric Lipp, Annick Desjardins, Henry S Friedman, Gordana Vlahovic, James Vredenburgh, Katherine B Peters
LESSONS LEARNED: Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall survival.Disease-expected toxicities should be considered when defining the clinical significance of an adverse event. For example, vascular thromboembolic events are common in brain tumor patients and should not be attributed to the study drug in the safety analysis...
April 17, 2018: Oncologist
Adriana Olar, Lindsey D Goodman, Khalida M Wani, Nicholas S Boehling, Devi S Sharma, Reema R Mody, Joy Gumin, Elizabeth B Claus, Frederick F Lang, Timothy F Cloughesy, Albert Lai, Kenneth D Aldape, Franco DeMonte, Erik P Sulman
BACKGROUND: Meningioma is the most common primary brain tumor and has a variable risk of local recurrence. While World Health Organization (WHO) grade generally correlates with recurrence, there is substantial within-grade variation of recurrence risk. Current risk stratification does not accurately predict which patients are likely to benefit from adjuvant radiation therapy (RT). We hypothesized that tumors at risk for recurrence have unique gene expression profiles (GEP) that could better select patients for adjuvant RT...
March 23, 2018: Oncotarget
Shoji Yomo, Kyota Oda
OBJECTIVES: Recent advances in target therapies have prolonged overall survival (OS) for patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. The impact of EGFR mutations on stereotactic radiosurgery (SRS) for brain metastases (BM) has yet to be determined. The present study sought to evaluate the efficacy and limitations of SRS, administered with EGFR-tyrosine kinase inhibitors (TKI), for BM from EGFR-mutant lung adenocarcinoma. MATERIALS AND METHODS: This retrospective observational study analyzed data from patients with BM arising from EGFR-mutant lung adenocarcinoma who received upfront Gamma Knife SRS between December 2010 and April 2016...
May 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Zongze He, Chao You, Dongdong Zhao
Glioblastoma (GB) is the most common and deadliest malignant primary brain tumor with a high recurrence. In this study, lncRNA UCA1/miR-182 axis has been regarded as a nodal driver of glioma invasion mediated by GB-associated stromal cells (GASCs) and GASC-secreted chemokine CXCL14. In clinical specimens, CXCL14 upregulation in GASCs also correlated with poor prognosis. Notably, CXCL14-high GASCs mediated lncRNA UCA1 upregulation and miR-182 downregulation in glioma cells. Moreover, miR-182 directly bound to the fructose-2,6-biphosphatase PFKFB2; UCA1/miR-182 axis thereby modulated GASC-induced glycolysis in glioma cells...
April 12, 2018: Biochemical and Biophysical Research Communications
Michael A Vogelbaum, Cathy Brewer, Gene H Barnett, Alireza M Mohammadi, David M Peereboom, Manmeet S Ahluwalia, Shenqiang Gao
OBJECTIVE Progress in management of high-grade gliomas (HGGs) has been hampered by poor access of potential therapeutics to the CNS. The Cleveland Multiport Catheter (CMC), which deploys 4 independent delivery microcatheters, was developed to be a reliable, high-volume delivery device for delivery of therapeutic agents to the brain and other solid organs. The authors undertook this first-in-human clinical trial effort to evaluate the delivery characteristics of the CMC in patients with HGGs. METHODS A series of pilot studies were launched after approval of a sponsor-investigator IND (investigational new drug) application to evaluate the delivery of topotecan and gadolinium-DTPA (Gd-DTPA) via the CMC in patients with recurrent HGG...
April 13, 2018: Journal of Neurosurgery
Hideoki Yokouchi, Masaki Miyazaki, Takeaki Miyamoto, Takafumi Minami, Fumio Tsuji, Kazuhito Oishi, Chikara Ebisui
Four patients with non-small-cell lung cancer(NSCLC), diagnosed with cN2 stage III A disease, by using CT and FDG-PET/ CT imaging, received 2 or 3 courses of platinum-based combination chemotherapy.The patients achieved partial response after chemotherapy and underwent surgery.Complete tumor resection was performed via upper lobectomy for 3 patients, but in 1 patient, interlobar metastatic lymph nodes remained after middle and lower bilobectomy.Two courses of postoperative chemotherapy were administered to 3 patients, but 1 patient could not receive postoperative chemotherapy due to complications...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Julia Onken, Franziska Staub-Bartelt, Peter Vajkoczy, Martin Misch
BACKGROUND: Tumor treating fields (TTFields) significantly prolong both progression-free and overall survival in patients with newly diagnosed glioblastoma (GBM). TTFields are delivered to the brain tumor via skin transducer arrays and should be applied for a minimum of 18 h per day (≥ 75% compliance). This may cause limited acceptance by patients because of obstacles in daily routine. So far, there are limited data on factors influencing therapy acceptance and compliance. METHODS: In this retrospective study, fourty-one patients with primary GBM or recurrent high grade glioma (rHGG) have been treated with TTFields in our department...
April 11, 2018: Journal of Neuro-oncology
Luyan Mu, Yu Long, Changlin Yang, Linchun Jin, Haipeng Tao, Haitao Ge, Yifan E Chang, Aida Karachi, Paul S Kubilis, Gabriel De Leon, Jiping Qi, Elias J Sayour, Duane A Mitchell, Zhiguo Lin, Jianping Huang
Background: Malignant gliomas are heterogeneous brain tumors with the potential for aggressive disease progression, as influenced by suppressive immunoediting. Given the success and enhanced potential of immune-checkpoint inhibitors in immunotherapy, we focused on the connections between genetic alterations affected by IDH1 mutations and immunological landscape changes and PDL-1 expression in gliomas. Methods: Paired surgically resected tumors from lower-grade gliomas (LGGs) and glioblastomas (GBM) were investigated, and a genetic analysis of patients' primary tumor samples culled from TCGA datasets was performed...
2018: Frontiers in Molecular Neuroscience
Ramesh S Doddamani, Rajesh K Meena, Dattaraj Sawarkar
Background: Meningiomas give rise to the dural tail sign (DTS) on contrast-enhanced magnetic resonance imaging (CEMRI). The presence of DTS does not always qualify for a meningioma, as it is seen in only 60-72% of cases. This sign has been described in various other lesions like lymphomas, metastasis, hemangiopericytomas, schwannomas and very rarely glioblastoma multiforme (GBM). The characteristics of dural-based GBMs are discussed here, as only eleven such cases are reported in the literature till date...
2018: Surgical Neurology International
Jun Yu, Jingwei Zheng, Weilin Xu, Jiaqi Weng, Liansheng Gao, Li Tao, Feng Liang, Jianmin Zhang
INTRODUCTION: It remains a great challenge to distinguish radiation necrosis from brain tumor recurrence. The meta-analysis was performed to assess the diagnostic accuracy of two different amino acid tracers of PET/CT. METHODS: We searched for studies in 3 databases: PubMed, Chinese Biomedical databases (CBM), Embase. The data were extracted from eligible studies and then processed with heterogeneity test, threshold effect test, and calculation of sensitivity (SEN), specificity (SPE) and areas under summary receiver operating characteristic curve (SROC)...
April 3, 2018: World Neurosurgery
Wen-Chiuan Tsai, Dueng-Yuan Hueng, Chii-Ruey Lin, Thomas C K Yang, Shin Nieh, Hong-Wei Gao
Patients with atypical meningiomas have a higher recurrence rate and poorer prognosis than patients with benign meningeal tumors. However, differentiating atypical from benign meningiomas based on fragmented specimens from brain tumor biopsy is complicated. We tested the association of DDX3X cytoplasmic expression and World Health Organization grading system in various subtypes of meningiomas. In our study, DDX3X expression was evaluated immunohistochemically in 10 non-neoplastic brain tissues and 71 meningiomas...
April 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
Arsela Prelaj, Sara Elena Rebuzzi, Giovanni Caffarena, Julio Rodrigo Giròn Berrìos, Silvia Pecorari, Carmela Fusto, Alessandro Caporlingua, Federico Caporlingua, Annamaria Di Palma, Fabio Massimo Magliocca, Maurizio Salvati, Silverio Tomao, Vincenzo Bianco
Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma that is treated with first-line therapy, using surgical resection followed by local radiotherapy and concomitant/adjuvant temozolomide (TMZ) treatment. GBM is characterised by a high local recurrence rate and a low response to therapy. Primitive neuroectodermal tumour (PNET) of the brain revealed a low local recurrence rate; however, it also exhibited a high risk of cerebrospinal fluid (CSF) dissemination. PNET is treated with surgery followed by craniospinal irradiation (CSI) and platinum-based chemotherapy in order to prevent CSF dissemination...
May 2018: Oncology Letters
Sze Kiat Tan, Anna Jermakowicz, Adnan K Mookhtiar, Charles B Nemeroff, Stephan C Schürer, Nagi G Ayad
Glioblastoma multiforme (GBM) is the most malignant primary adult brain tumor. The current standard of care is surgical resection, radiation, and chemotherapy treatment, which extends life in most cases. Unfortunately, tumor recurrence is nearly universal and patients with recurrent glioblastoma typically survive <1 year. Therefore, new therapies and therapeutic combinations need to be developed that can be quickly approved for use in patients. However, in order to gain approval, therapies need to be safe as well as effective...
2018: Frontiers in Pharmacology
Takayuki Yasuda, Yoshihiro Muragaki, Masayuki Nitta, Kazunari Miyamoto, Yuko Oura, Takuo Henmi, Sanshiro Noguchi, Hideaki Oda, Taiichi Saito, Takashi Maruyama, Shoko Atsuchi, Naohisa Miura, Takakazu Kawamata
OBJECT: This study aimed to evaluate the efficacy of stereotactic radiotherapy combined with bevacizumab (SRT-Bv) compared with Bv treatment for recurrent high-grade gliomas (HGGs). METHODS: Herein, data for patients with recurrent HGG who received SRT and Bv (n = 29) or Bv (n = 29) between June 2014 and September 2016 were retrospectively analyzed. All patients received conventional radiotherapy (total 60 Gy) before this study. SRT was administered at a median dose of 42 Gy in 3-7 fractions...
March 31, 2018: World Neurosurgery
Noriaki Tomura, Toshiyuki Saginoya, Hiromi Goto
OBJECTIVE: The aim of this study was to determine the assessment of positron emission tomography-computed tomography using C-methionine (MET PET/CT) for World Health Organization (WHO) grades II and III meningiomas; MET PET/CT was compared with PET/CT using F-fluorodeoxy glucose (FDG PET/CT). METHODS: This study was performed in 17 cases with residual and/or recurrent WHO grades II and III meningiomas. Two neuroradiologists reviewed both PET/CT scans. For agreement, the κ coefficient was measured...
April 2, 2018: Journal of Computer Assisted Tomography
Chunhua Wang, Songsheng Shi, Quan Chen, Shuqian Lin, Rui Wang, Saizhen Wang, Chunmei Chen
Malignant gliomas are the most common brain tumors with high rates of recurrence and mortality. Novel approaches are in research, and immunotherapy emerges as a promising strategy. Recently, scientific attention has been focused on Ganoderma lucidum polysaccharides (GL-PS), one of the critical bioactive components of G lucidum, which have been recognized as a promising natural source of immunomodulatory and anticancer compounds. It remains unknown whether the GL-PS have any immunomodulatory and anticancer effects on brain glioma...
March 1, 2018: Integrative Cancer Therapies
Rui Reinas, Raul B Santos, Djamel Kitumba, Antónia Furtado, Óscar L Alves, Mário Resende
Carcinoid tumors are generally indolent neoplasms. Brain metastases are rare and when present, yield a poor prognosis. We present the case of a 76-year old female surgically treated for an atypical bronchial carcinoid, staged as T2aN0M0G2. Without further adjuvant treatment she remained stable for four years, when she presented with headaches and gait imbalance. Brain MRI revealed a midline, intra-axial infratentorial lesion that was completely removal, of which histolology confirmed a carcinoid metastasis...
April 2, 2018: British Journal of Neurosurgery
Dipongkor Saha, Hiroaki Wakimoto, Cole W Peters, Slawomir J Antoszczyk, Samuel D Rabkin, Robert L Martuza
PURPOSE: Glioblastoma (GBM), a fatal brain cancer, contains a subpopulation of GBM stem-like cells (GSCs) that contribute to resistance to current therapy. Angiogenesis also plays a key role in GBM progression. Therefore, we developed a strategy to target the complex GBM microenvironment, including GSCs and tumor vasculature. EXPERIMENTAL DESIGN: We evaluated the cytotoxic effects of VEFGR tyrosine kinase inhibitor (TKI) axitinib in vitro and then tested anti-tumor efficacy of axitinib in combination with oncolytic herpes simplex virus (oHSV) expressing anti-angiogenic cytokine murine IL12 (G47Δ-mIL12) in two orthotopic GSC-derived GBM models: patientderived recurrent MGG123 GSCs, forming vascular xenografts in immune-deficient mice, and mouse 005 GSCs, forming syngeneic tumors in immune-competent mice...
March 29, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Jianling Yuan, Richard Lee, Kathryn Ellen Dusenbery, Chung K Lee, Damien C Mathew, Paul Wayne Sperduto, Yoichi Watanabe
Purpose: Repeat stereotactic radiosurgery (SRS) is an attractive alternative to whole brain radiation therapy (WBRT) for treatment of recurrent brain metastases (BM). The purpose of this study is to determine the cumulative doses to the brain and critical normal structures in patients who underwent repeat courses of Gamma Knife (GK) SRS. Materials and methods: We retrospectively identified ten patients who received at least three GK-SRS sessions for multiply recurrent BM at our institution from 2013 to 2016...
2018: Frontiers in Oncology
Sonia Tejada, Ricardo Díez-Valle, Pablo D Domínguez, Ana Patiño-García, Marisol González-Huarriz, Juan Fueyo, Cande Gomez-Manzano, Miguel Angel Idoate, Joanna Peterkin, Marta M Alonso
Diffuse intrinsic pontine gliomas (DIPGs) are aggressive glial brain tumors that primarily affect children, for which there is no curative treatment. Median overall survival is only one year. Currently, the scientific focus is on expanding the knowledge base of the molecular biology of DIPG, and identifying effective therapies. Oncolytic adenovirus DNX-2401 is a replication-competent, genetically modified virus capable of infecting and killing glioma cells, and stimulating an anti-tumor immune response. Clinical trials evaluating intratumoral DNX-2401 in adults with recurrent glioblastoma have demonstrated that the virus has a favorable safety profile and can prolong survival...
2018: Frontiers in Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"